Patient's quality of life after surgery and radiotherapy for extremity soft tissue sarcoma - a retrospective single-center study over ten years.
Health related quality of life
QLQ-C30
Sarcoma major complication rates
Sarcoma radiotherapy
Soft tissue sarcoma
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
08 Nov 2019
08 Nov 2019
Historique:
received:
31
05
2019
accepted:
22
10
2019
entrez:
10
11
2019
pubmed:
11
11
2019
medline:
6
2
2020
Statut:
epublish
Résumé
The purpose of this study is to analyze major complication rates and different aspects of health-related quality of life (HRQoL) in extremity soft tissue sarcoma (STS) patients treated with or without radio (chemo) therapy and surgery. We performed a retrospective analysis of all patients who underwent Extremity STS excision from 2004 to 2014 (182 patients included). Patients' data were collected from patients' records. HRQoL was assessed by using EORTC QLQ-C30. A total of 182 patients underwent sarcoma resection. After neoadjuvant radiochemotherapy (RCT), the major-complication rate amounted to 28% (vs. 7%, no radiotherapy, p < 0.001). Major-complication rates after adjuvant radiotherapy (RT) occurred in 8% (vs. 7%, no radiotherapy, p = 0.265). Comparison QoL scores between treating with neoadjuvant RCT or without RT revealed significant worse scores with neoadjuvant RCT. Further stratification of disease control of these patients showed significant reduced scores in the group of disease-free patients with neoadjuvant RCT compared to irradiated disease-free patients. To date, there have only been a few investigations of QoL in STS. Retrospective study on quality of life have limitations, like a lack of baseline evaluation of QoL. Patient candidated to radiation therapy could have had worse QoL baseline due to more advanced disease. Disease status of the patients who answered the questionnaires could have been an influence of QoL and we could show reduced scores in the group of disease-free patients with neoadjuvant RCT, but not for the patients with recurrence or metastasis, so it is very hard to discriminate whether radiation therapy could really have an impact or not. This study might assist in further improving the understanding of QoL in STS patients and may animate for prospective studies examining the oncological therapies impact on HRQoL.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The purpose of this study is to analyze major complication rates and different aspects of health-related quality of life (HRQoL) in extremity soft tissue sarcoma (STS) patients treated with or without radio (chemo) therapy and surgery.
METHODS
METHODS
We performed a retrospective analysis of all patients who underwent Extremity STS excision from 2004 to 2014 (182 patients included). Patients' data were collected from patients' records. HRQoL was assessed by using EORTC QLQ-C30.
RESULTS
RESULTS
A total of 182 patients underwent sarcoma resection. After neoadjuvant radiochemotherapy (RCT), the major-complication rate amounted to 28% (vs. 7%, no radiotherapy, p < 0.001). Major-complication rates after adjuvant radiotherapy (RT) occurred in 8% (vs. 7%, no radiotherapy, p = 0.265). Comparison QoL scores between treating with neoadjuvant RCT or without RT revealed significant worse scores with neoadjuvant RCT. Further stratification of disease control of these patients showed significant reduced scores in the group of disease-free patients with neoadjuvant RCT compared to irradiated disease-free patients.
DISCUSSION
CONCLUSIONS
To date, there have only been a few investigations of QoL in STS. Retrospective study on quality of life have limitations, like a lack of baseline evaluation of QoL. Patient candidated to radiation therapy could have had worse QoL baseline due to more advanced disease. Disease status of the patients who answered the questionnaires could have been an influence of QoL and we could show reduced scores in the group of disease-free patients with neoadjuvant RCT, but not for the patients with recurrence or metastasis, so it is very hard to discriminate whether radiation therapy could really have an impact or not.
CONCLUSION
CONCLUSIONS
This study might assist in further improving the understanding of QoL in STS patients and may animate for prospective studies examining the oncological therapies impact on HRQoL.
Identifiants
pubmed: 31703704
doi: 10.1186/s12955-019-1236-4
pii: 10.1186/s12955-019-1236-4
pmc: PMC6842193
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Références
Ann Surg Oncol. 2018 Mar;25(3):754-767
pubmed: 28895107
J Clin Oncol. 2000 Oct 1;18(19):3378-83
pubmed: 11013278
Surgery. 1982 Jan;91(1):17-23
pubmed: 7054901
J Surg Oncol. 2018 Jul;118(1):184-191
pubmed: 29878365
Trials. 2016 Apr 15;17:187
pubmed: 27079379
Qual Life Res. 2006 Nov;15(9):1439-46
pubmed: 16732468
J Surg Oncol. 2015 Apr;111(5):599-603
pubmed: 25366825
J Surg Oncol. 2018 Sep;118(3):525-531
pubmed: 30259517
Eur J Surg Oncol. 2017 Sep;43(9):1733-1739
pubmed: 28579008
Am J Clin Oncol. 2016 Dec;39(6):600-603
pubmed: 25036470
Clin Orthop Relat Res. 2010 Nov;468(11):3012-8
pubmed: 20700676
Wien Klin Wochenschr. 2011 Aug;123(15-16):488-95
pubmed: 21739209
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Cell Mol Med. 2015 Sep;19(9):2098-107
pubmed: 26010680
Cancer. 2015 Sep 1;121(17):2933-41
pubmed: 26033286
Health Qual Life Outcomes. 2017 May 19;15(1):107
pubmed: 28526051
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
Orthop Rev (Pavia). 2015 Jun 16;7(2):5920
pubmed: 26330994
Dis Esophagus. 2011 Jan;24(1):39-47
pubmed: 20819100
Am Soc Clin Oncol Educ Book. 2015;:e634-42
pubmed: 25993234
Qual Life Res. 2004 Mar;13(2):481-8
pubmed: 15085920
Oncology (Williston Park). 2016 Jan;30(1):99-106
pubmed: 26791852
Radiother Oncol. 2016 Apr;119(1):14-21
pubmed: 26718153
Curr Treat Options Oncol. 2004 Dec;5(6):477-88
pubmed: 15509481
J Cell Mol Med. 2015 Feb;19(2):283-96
pubmed: 25598217
Oncol Nurs Forum. 1998 Jun;25(5):915-20
pubmed: 9644708
Ann Surg. 1982 Sep;196(3):305-15
pubmed: 7114936
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53
pubmed: 17090186
J Radiat Res. 2013 Jul;54 Suppl 1:i43-8
pubmed: 23824125
J Surg Oncol. 2018 Sep;118(4):614-620
pubmed: 30196551
Anticancer Res. 2014 Oct;34(10):5251-62
pubmed: 25275017
J Surg Oncol. 2015 Sep;112(4):338-43
pubmed: 26250782
Am J Clin Oncol. 2018 Apr;41(4):348-356
pubmed: 26886948
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Ann Surg Oncol. 2006 Jun;13(6):864-71
pubmed: 16614886
Health Qual Life Outcomes. 2018 Jun 4;16(1):114
pubmed: 29866185
Sarcoma. 2012;2012:740279
pubmed: 22550425
Ann Surg Oncol. 2010 May;17(5):1367-74
pubmed: 20217260
Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9
pubmed: 1938558
Surg Oncol. 2014 Sep;23(3):155-60
pubmed: 25085344
Support Care Cancer. 2014 Sep;22(9):2479-87
pubmed: 24728584
Cancer. 2015 Apr 15;121(8):1214-22
pubmed: 25537381